Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer

Inclusion Criteria: * Phase 1: histopathological-documented, measurable or non-measurable unresectable, advanced primary or recurrent SCLC, NSCLC or mesothelioma * Phase 2: measurable, unresectable advanced or recurrent SCLC * A life expectancy \> 3 months * Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1 at study entry * Echocardiogram or multigated acquisition (MUGA) scan with left ventricular ejection fraction (LVEF) ≥ 50%, or ≥ institution's established lower limit of normal * Adequate hematologic, hepatic, renal and lung function Exclusion Criteria: * Subject received cytotoxic anti-cancer chemotherapy, orally available signaling pathway-targeted therapy, hormonal therapy, radiotherapy, immunotherapy, or investigational agents within 3 weeks prior to the first dose * Subject received monoclonal antibodies within 4 weeks of the first dose * Major surgery within 4 weeks prior to the first dose * Known symptomatic brain metastases * Clinically significant cardiovascular disease * Leptomeningeal disease * Uncontrolled intercurrent illness including ongoing or active infection, uncontrolled diabetes, etc * Known HIV disease or acquired immunodeficiency syndrome-related illness * A psychiatric illness, disability or social situation * Hypersensitivity reaction to monoclonal antibodies, other therapeutic proteins * A history of primary brain/CNS malignancy * Neurological paraneoplastic syndrome